Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 5/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2045687 | 0.80 | CPT1A (0.40) | SMN1; SMN2CNR1CPT1ARAB9ANPSR1 | |
| SCHEMBL2046819 | 0.78 | LMNA (0.41) | SMN1; SMN2LMNAKDM4ECPT1AMMP9 | |
| SCHEMBL2047441 | 0.74 | CPT1A (0.44) | CNR1CPT1A | |
| SCHEMBL2045115 | 0.73 | CPT1A (0.42) | SMN1; SMN2ALDH1A1CPT1AMMP9TDP1 | |
| SCHEMBL27847405 | 0.71 | KDM4E (0.39) | LMNAKDM4E | |
| SCHEMBL2049685 | 0.71 | GABRA1 (0.41) | SMN1; SMN2LMNAKDM4ECPT1AMMP9 | |
| Etallobarbital SCHEMBL713588 | 0.70 | LMNA (0.64) | SMN1; SMN2ALDH1A1LMNAKDM4ECPT1A | |
| SCHEMBL11677956 | 0.69 | SMN1; SMN2 (0.46) | SMN1; SMN2LMNAKDM4ENPSR1ELANE | |
| SCHEMBL2050980 | 0.69 | CPT1A (0.36) | CPT1AMMP9NPSR1ELANE | |
| SCHEMBL3504596 | 0.68 | MMP9 (0.49) | SMN1; SMN2ALDH1A1LMNACPT1AMMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11717549-B2 | Steviol glycoside solubility enhancers | CARGILL, INCORPORATED (US) | 2023-08-08 | — | — | US | disclosed |
| US-20220323528-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | CARGILL, INCORPORATED (US) | 2022-10-13 | — | — | US | disclosed |
| US-20190223481-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | CARGILL, INCORPORATED (US) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220323528-A1 | STEVIOL GLYCOSIDE SOLUBILITY ENHANCERS | SI, TAS2R7, TAS2R31 | SMN1; SMN2 289/4885ALDH1A1 2625/4885MAPT 3044/4885 |
| US-11717549-B2 | Steviol glycoside solubility enhancers | SI, TAS2R7, TAS2R31 | SMN1; SMN2 289/4885ALDH1A1 2625/4885MAPT 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.